Company Filing History:
Years Active: 2025
Title: Klaus Ehrmann: Innovator in Myopia Management
Introduction
Klaus Ehrmann is a notable inventor based in Sydney, Australia. He has made significant contributions to the field of ophthalmic lenses, particularly in managing myopia. With a total of 3 patents, his work focuses on innovative solutions to eye-length disorders.
Latest Patents
Ehrmann's latest patents include groundbreaking inventions aimed at transforming single vision ophthalmic lenses into effective myopia management tools. One of his notable patents is for optical films with non-refractive opaque features. This invention provides methods for the prescription, selection, supply, and fitting of optical films that enhance standard single vision spectacles. The non-refractive opaque features are designed to increase retinal ganglion cell activity, potentially decelerating the progression of myopia in wearers.
Another significant patent is for a freeform contact lens solution specifically designed for myopia management. This invention features a contact lens with an optical zone and a non-optical peripheral carrier zone. The optical zone is configured to provide correction for the eye, while the peripheral zone is designed to deliver varying stop signals to help reduce myopia progression.
Career Highlights
Throughout his career, Klaus Ehrmann has worked with several companies, including Nthalmic Holding Pty Ltd and Brighten Optix Corporation. His experience in these organizations has allowed him to develop and refine his innovative ideas in the field of optics.
Collaborations
Ehrmann has collaborated with notable professionals in the industry, including Ravi Chandra Bakaraju and Fabian Conrad. These partnerships have contributed to the advancement of his inventions and the overall progress in myopia management.
Conclusion
Klaus Ehrmann's contributions to the field of ophthalmic lenses demonstrate his commitment to innovation and improving eye health. His patents reflect a deep understanding of myopia management and a dedication to developing effective solutions for those affected by eye-length disorders.